免疫靶向药物治疗非小细胞肺癌的最新研究进展

doi:10.3969/j.issn.2095-1264.2023.01.02

首页 > 过刊浏览>2023年第1期 >11-16. DOI:10.3969/j.issn.2095-1264.2023.01.02

免疫靶向药物治疗非小细胞肺癌的最新研究进展
DOI:
                        10.3969/j.issn.2095-1264.2023.01.02
                    
作者:
                        
                        
                    
作者单位:1.湖南省中医药大学附属第一医院，湖南 长沙，410000;2.中南大学湘雅医学院，湖南 长沙，410013;3.中南大学湘雅二医院 药学部，湖南 长沙，410011;4.湖南中医药大学，湖南 长沙，410208
作者简介:陈景，女，药师，研究方向：临床药物治疗。
通讯作者:彭词艳，男，硕士，主管药师，研究方向：临床药物治疗和药物经济学。
中图分类号:R734.2
基金项目:

Recent advances in immune-targeted therapy for non-small cell lung cancer

Author:

Affiliation:

1.The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha, 410000, Hunan, China;2.Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan, China;3.Department of Pharmacology, Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China;4.Hunan University of Traditional Chinese Medicine, Changsha, 410208, Hunan, China

Fund Project:

摘要

图/表

访问统计

参考文献

相似文献

引证文献

资源附件

文章评论

摘要:

随着精准医学和生物技术的发展，除了EGFR基因，非小细胞肺癌中ALK、BRAF、HER2、KRAS、MEK1、MET、NRAS、PIK3CA、RET、ROS1等多个基因突变的研究也逐渐取得更大突破。相比化疗时代，靶向和免疫治疗显著延长了晚期非小细胞肺癌患者的生存时间，使晚期转移性肺癌患者的中位生存期延长至23～27个月，5年生存率达14.6%以上。2020年，非小细胞肺癌新药的进展和获批均呈现井喷状态，特别是靶向和免疫治疗领域产生了范式转变，每一项成功的数据都为晚期非小细胞肺癌患者的生存带来了更多的选择和希望。本文拟对2020年新上市和获批一线治疗非小细胞肺癌的免疫靶向新药进行介绍和总结，以期为临床用药提供一定的理论基础。

Abstract:

With the development of precision medicine and biological technology, in addition to the EGFR, studies on ALK, BRAF, HER2, KRAS, MEK1, MET, NRAS, PIK3CA, RET, ROS1 and other gene mutations in non-small cell lung cancer have gradually made greater breakthroughs. Compared with chemotherapy, targeted and immune treatment increased the survival time of advanced non-small cell lung cancer patients significantly, prolonged the median survival time of advanced metastatic lung cancer patients up to 23～27 months, and raised the 5-year survival rate beyond 14.6%. In 2020, the development and approval of new drugs for non-small cell lung cancer was in a spurt, especially in the field of targeted drugs and immunotherapy. Each successful data brought more choices and hopes for the survival of patients with advanced non-small cell lung cancer. To sum up, this paper intended to introduce and summarize the newly marketed and approved biotargeted new drugs for the first-line treatment of non-small cell lung cancer in 2020, so as to provide a theoretical basis for clinical medication.